SWA
CHRS icon

Sutton Wealth Advisors’s Coherus Oncology CHRS Stock Holding History

Sutton Wealth Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,473
Closed -$27.5K – 952
2022
Q4 		$27.5K Sell
3,473
-61
-2% -$469 0.01% 577
2022
Q3 		$34K Sell
3,534
-22
-0.6% -$223 0.01% 482
2022
Q2 		$25.7K Buy
3,556
+2,259
+174% +$19.6K 0.01% 586
2022
Q1 		$16.7K Buy
1,297
+281
+28% +$3.57K 0.01% 771
2021
Q4 		$16.2K Buy
1,016
+491
+94% +$8.59K 0.01% 772
2021
Q3 		$8.44K Sell
525
-76
-13% -$1.11K ﹤0.01% 963
2021
Q2 		$8.31K Sell
601
-51
-8% -$722 ﹤0.01% 963
2021
Q1 		$9.53K Buy
652
+110
+20% +$1.87K ﹤0.01% 893
2020
Q4 		$9.42K Sell
542
-268
-33% -$4.77K ﹤0.01% 830
2020
Q3 		$14.9K Buy
810
+268
+49% +$4.99K 0.01% 628
2020
Q2 		$9.68K Buy
+542
New +$9.17K 0.01% 713

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sutton Wealth Advisors's CHRS Position: Q1 2023 in Review

Sutton Wealth Advisors sold out of Coherus Oncology (CHRS) in Q1 2023, closing a stake of 3,473 shares — an estimated $27.5K sold.

Sutton Wealth Advisors first reported a position in CHRS in Q2 2020 and held it in 11 quarters. The position peaked at $34K in Q3 2022. 163 funds tracked by Wall St. Rank hold CHRS as of Q1 2023.

  • Sutton Wealth Advisors reported no remaining Coherus Oncology position as of Q1 2023 after selling out during the quarter.
  • Sutton Wealth Advisors sold 3,473 Coherus Oncology shares in Q1 2023, an estimated $27.5K.
  • Sutton Wealth Advisors first reported a position in Coherus Oncology in Q2 2020 and held it in 11 quarters.
  • Sutton Wealth Advisors's Coherus Oncology position peaked at $34K in Q3 2022.
  • 163 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2023.

Based on Sutton Wealth Advisors's 13F filing for Q1 2023, filed 7 Nov 2023.